Recombinate - Antihemophilic Factor (Recombinant)
In stock
Reconfirm the price with seller
- Customer pickup,
- Courier
- In detail
Products of other enterprises
Description
The information contained in this page is intended for Indian healthcare professionals only.
RECOMBINATE was the first genetically engineered, non-plasma-derived factor VIII therapy in the world.1 RECOMBINATE has over 18 years of post-licensure clinical experience.2,3 To date, no confirmed spontaneous reports of hepatitis A, B, C, or HIV transmission or CJV have been received that can be definitively linked to RECOMBINATE administration.4
Indications :
RECOMBINATE is indicated in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes and for the perioperative management of patients with hemophilia A.4 RECOMBINATE is not indicated for von Willebrand's disease.
RECOMBINATE was the first genetically engineered, non-plasma-derived factor VIII therapy in the world.1 RECOMBINATE has over 18 years of post-licensure clinical experience.2,3 To date, no confirmed spontaneous reports of hepatitis A, B, C, or HIV transmission or CJV have been received that can be definitively linked to RECOMBINATE administration.4
Indications :
RECOMBINATE is indicated in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes and for the perioperative management of patients with hemophilia A.4 RECOMBINATE is not indicated for von Willebrand's disease.
Contact the seller
Recombinate - Antihemophilic Factor (Recombinant)